Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 06, 2025, titled "Press Release on the Audited Financial Results for the quarter and Financial Year ended 31st March, 2025".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals reported consolidated Q4 FY25 results with Net Sales of Rs. 1,770 Cr, up 17% from Rs. 1,517 Cr in Q4 FY24. EBITDA grew 9% to Rs. 286 Cr (16% margin), while Profit Before Tax rose 5% to Rs. 192 Cr and Net Profit stood at Rs. 157 Cr. For the full year FY25, total revenue grew 7% to Rs. 6,672 Cr, driven by strong Ex-US international generics (up 43% in Q4 to Rs. 375 Cr) and US generics (up 20% to Rs. 508 Cr). The India branded business grew 8% to Rs. 545 Cr, supported by specialty therapies, gynaecology, anti-diabetic, and animal health segments, while the API business grew modestly by 4% to Rs. 342 Cr but declined 9% for the full year.
Solid broad-based growth across India, US, and Ex-US markets signals improving momentum, though the full-year API decline and modest 5% PBT growth suggest margin pressures. Investors will likely view the strong Ex-US and US performance as positives, but the API weakness warrants monitoring.